Loading
Jennifer Litton led the EMBRACA trial that brought talazoparib to BRCA-mutated breast cancer.
Jennifer Litton is Vice President for Clinical Research and Professor of Breast Medical Oncology at MD Anderson Cancer Center. A breast medical oncologist specialising in BRCA and PARP inhibitors, she was principal investigator of EMBRACA, the trial that brought talazoparib to BRCA-mutated breast cancer, and of neoadjuvant talazoparib studies in germline BRCA carriers. Her papers report talazoparib in advanced breast cancer with a germline BRCA mutation in the New England Journal of Medicine and neoadjuvant talazoparib for operable breast cancer with a germline BRCA pathogenic variant in the Journal of Clinical Oncology. She oversees clinical research operations across MD Anderson, with work spanning triple-negative and HR-positive breast cancer and germline testing.
| Title | Journal | Year |
|---|---|---|
| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation | New England Journal of Medicine | 2018 |
| Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant | Journal of Clinical Oncology | 2020 |
Shares EMBRACA, Talazoparib, PARP inhibitors, BRCA1 / BRCA2 (HRD).
Shares PARP inhibitors, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing.
Shares MD Anderson Cancer Center, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing.
Shares PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
Shares EMBRACA, PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD).
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Germline (hereditary) testing, Triple-negative breast cancer (TNBC).
Shares EMBRACA, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem.
Shares PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).